Almeda Ventures Limited Partnership (AMDA) Fair Value & Analysis
Healthcare · Il · Market cap 47.2M ILA · ISIN IL0011689622
Strengths
Risks
Fair value as of: Aug 27, 2026
From 12 valuation models · updated yesterday
Share price +10.7% over the past month.
A solid business, but trading 74% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (1.76 ILA). The favourable scenario is already priced in.
- Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
60‑month range 0.8530 ILA – 6.07 ILA · fair‑value band 1.05 ILA – 1.76 ILA · the 2.45 ILA price screens above the 1.41 ILA fair value. Dashed = 300-day average. As of Aug 27, 2026.
Analysis
Almeda Ventures Limited Partnership (AMDA) currently trades at 2.45 ILA, while our model-based Fair Value estimate is 1.41 ILA, implying the stock looks roughly 42.5% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
It earns a return on equity of 7.2%. Fundamentals as of Aug 27, 2026
Our scenario range runs from 1.05 ILA (bear case) to 1.76 ILA (bull case); at 2.45 ILA, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at -42%, AMDA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 12 models by family
Widest divergence: Growth Earnings (1.62 ILA) versus Earnings-Based (0.6200 ILA). Highest evidence: Growth-Adj P/E (68).
Notify me when AMDA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 83
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Almeda Ventures Limited Partnership is a venture capital firm specializing in seed, start up, early venture and middle market investments. The firm seeks to invest in health technology with focus on public R&D partnership, medical devices, digital health and bio-convergence; life sciences research and development company.
Full company description
Almeda Ventures Limited Partnership is a venture capital firm specializing in seed, start up, early venture and middle market investments. The firm seeks to invest in health technology with focus on public R&D partnership, medical devices, digital health and bio-convergence; life sciences research and development company. It prefers to invest in Israel, USA and Europe. Almeda Ventures Limited Partnership was founded in 2020 and is based in Tel Aviv, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Almeda Ventures Limited Partnership reported revenue of 87.7K ILA in FY2025 versus 1.6M ILA in FY2021, a compound −51.6%/yr. Reported net income was 1.9M ILA in FY2025, compounding +145.6%/yr from FY2021.
AMDA screens 42% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 130 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $244.91 | $91.49 | -63% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $104.27 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | -69% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.74 | $25.91 | +5% |
| Privia Health Group PRVA | $21.07 | $5.26 | -75% |
Compare Almeda Ventures Limited Partnership with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Almeda Ventures Limited Partnership (AMDA) overvalued or undervalued?
What is the fair value of AMDA?
What is the quality score of AMDA?
What is the net profit margin of AMDA?
Does Almeda Ventures Limited Partnership pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Almeda Ventures Limited Partnership in the live analysis
One click puts Almeda Ventures Limited Partnership on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.